Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Change in Accured Expenses (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Change in Accured Expenses for 2 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 16.16% to $1.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $3.4 million, a N/A change, with the full-year FY2025 number at $4.6 million, up 1144.47% from a year prior.
  • Change in Accured Expenses was $1.4 million for Q4 2025 at Kestra Medical Technologies, up from -$860000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q2 2025 to a low of -$860000.0 in Q3 2025.